KRAS inhibitor-3 is an inhibitor of KRAS inhibitor. KRAS inhibitor-3 binds to WT and oncogenic KRAS mutants with high affinity ( K D : 0.28 μM for KRAS WT, 0.63 μM for KRAS G12C, 0.37 μM for KRAS G12D, 0.74 μM for KRAS Q61H). KRAS inhibitor-3 also disrupts interaction of KRAS with Raf In Vitro KRAS inhibitor-3 (Compound 11, 0-1 μM, 72 h) inhibits growth of KRAS-expressing lung cancer cells. KRAS inhibitor-3 (0-5 μM) decreases the p-ERK levels in BHK cells stably expressing KRASG12D. KRAS inhibitor-3 (1 μM, 2 h) disrupts interaction of KRAS with Raf. KRAS inhibitor-3 (0-5 μM) decreases both p-ERK and p-cRaf levels in BHK cells expressing KRASG12D and KRASG12V. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: BHK cells stably expressing KRASG12D Concentration: 0.01, 0.1, 0.5 1, 5 μM Incubation Time: Result: Decreased the p-ERK levels at >1μM. Form:Solid IC50& Target:K-Ras WT 0.28 μM (EC 50 ) KRAS(G12C) 0.63 μM (EC 50 ) KRas G12D 0.37 μM (EC 50 ) KRas Q61H 0.74 μM (EC 50 )